Levetiracetam Ameliorates L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats Inducing Critical Molecular Changes in the Striatum
L-DOPA-induced dyskinesias (LID) remain a major problem of long-term therapy of Parkinson’s disease. Levetiracetam, a new antiepileptic drug, has been shown to reduce LID, but the mechanisms underlying its effects are unknown. In this study, we assessed the effect of levetiracetam on key mediators o...
Saved in:
Main Authors: | Huan Du, Shuke Nie, Guiqin Chen, Kai Ma, Yan Xu, Zhentao Zhang, Stella M. Papa, Xuebing Cao |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2015-01-01
|
Series: | Parkinson's Disease |
Online Access: | http://dx.doi.org/10.1155/2015/253878 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Corticostriatal Plastic Changes in Experimental L-DOPA-Induced Dyskinesia
by: Veronica Ghiglieri, et al.
Published: (2012-01-01) -
Role of Serotonin Neurons in L-DOPA- and Graft-Induced Dyskinesia in a Rat Model of Parkinson's Disease
by: Eunju Shin, et al.
Published: (2012-01-01) -
7,8-Dihydroxyflavone Protects Nigrostriatal Dopaminergic Neurons from Rotenone-Induced Neurotoxicity in Rodents
by: Shuke Nie, et al.
Published: (2019-01-01) -
Understanding and Prevention of “Therapy-” Induced Dyskinesias
by: Iciar Aviles-Olmos, et al.
Published: (2012-01-01) -
Clinical Aspects and Management of Levodopa-Induced Dyskinesia
by: Nicola Tambasco, et al.
Published: (2012-01-01)